Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.54 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 3/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 6/20 | 0.45 |
| ▸ | CTSK | P43235 | 5/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.44 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.44 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1386285 | 0.91 | PPARG (0.47) | ITGB3ITGA2BPPARGCTSSCTSK | |
| SCHEMBL13866927 | 0.90 | PPARG (0.44) | ITGB3ITGA2BPPARGCTSSCTSK | |
| SCHEMBL3874442 | 0.90 | PPARG (0.44) | ITGB3ITGA2BPPARGCTSSCTSK | |
| SCHEMBL3966005 | 0.85 | PPARG (0.44) | ITGB3ITGA2BPPARGFFAR1PPARA | |
| SCHEMBL15844982 | 0.85 | PPARG (0.51) | PPARGFFAR1PPARA | |
| Hydrochloric Acid SCHEMBL4158143 | 0.84 | PPARG (0.50) | PPARGFFAR1PPARA | |
| SCHEMBL13875934 | 0.84 | PPARG (0.52) | PPARGFFAR1PPARA | |
| SCHEMBL3966853 | 0.83 | MME (0.48) | ITGB3ITGA2BACEPPARGFFAR1 | |
| SCHEMBL3968290 | 0.83 | FFAR1 (0.50) | ITGB3ITGA2BPPARGFFAR1PPARA | |
| SCHEMBL3968751 | 0.83 | PPARG (0.46) | PPARGFFAR1PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4833072-B2 | — | — | 2011-12-07 | — | — | JP | claimed |
| EP-1583529-B1 | AMINO ACID PHENOXY ETHERS, THEIR PREPARATION AND USES | BEXEL PHARMACEUTICALS INC (US) | 2011-11-09 | — | — | EP | claimed |
| EP-1583529-A4 | AMINO ACID PHENOXY ETHERS | BEXEL PHARMACEUTICALS INC (US) | 2007-07-04 | — | — | EP | claimed |
| EP-1583529-A2 | AMINO ACID PHENOXY ETHERS | Bexel Pharmaceuticals Inc (US) | 2005-10-12 | — | — | EP | claimed |
| US-6794401-B2 | thiazolidin-2,4-diones or -oxazolidin-2,4-diones; metabolic Syndrome-X; immunological diseases, inflammation, obesity, hyperlipidemia, hypertension, diabetes; increased leptin level; no liver toxicity; inhibits TNF alpha , IL-6 and IL-1 beta; no affinity for PPAR-g; non-adipogenic | BEXEL PHARMACEUTICALS, INC. | 2004-09-21 | — | — | US | claimed |
| WO-2004066964-A9 | AMINO ACID PHENOXY ETHERS | BEXEL PHARMACEUTICALS INC (US) | 2004-09-02 | — | — | WO | claimed |
| WO-2004066964-A2 | AMINO ACID PHENOXY ETHERS | BEXEL PHARMACEUTICALS, INC. (US) | 2004-08-12 | — | — | WO | claimed |
| US-20040142991-A1 | Amino acid phenoxy ethers | BEXEL PHARMACEUTICALS, INC. | 2004-07-22 | — | — | US | claimed |
| EP-1848700-B1 | SALTS OF (S)-2-AMINO-3-{4-[4-(2,4-DIOXO-THIAZOLIDIN-5-YLMETHYL)-PHENOXY]-PHENYL}-PROPIONIC ACID AND ITS METHYL ESTER AS INTERLEUKIN INHIBITORS FOR THE TREATMENT OF OBESITY OR DIABETES | BEXEL PHARMACEUTICALS INC (US) | 2015-12-30 | — | — | EP | disclosed |
| EP-1583529-B1 | AMINO ACID PHENOXY ETHERS, THEIR PREPARATION AND USES | BEXEL PHARMACEUTICALS INC (US) | 2011-11-09 | — | — | EP | disclosed |
| US-7521465-B2 | Diphenyl ether derivatives | BEXEL PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| EP-1848700-A1 | 5- [4- (4- (2 -AMINO- 2 -METHOXYCARBONYLETHYL) PHENOXY) BENZILIDENE]THIAZOLIDIN-2 , 4-DION E DERIVATIVES AND RELATED COMPOUNDS FOR REDUCING GLUCOSE, CHOLESTEROL AND TRIGLYCERIDE LEVELS IN PLASMA | Bexel Pharmaceuticals Inc (US) | 2007-10-31 | — | — | EP | disclosed |
| EP-1583529-A4 | AMINO ACID PHENOXY ETHERS | BEXEL PHARMACEUTICALS INC (US) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006089225-A1 | 5- [4- (4- (2 -AMINO- 2 -METHOXYCARBONYLETHYL) PHENOXY) BENZILIDENE] THIAZOLIDIN-2 , 4-DION E DERIVATIVES AND RELATED COMPOUNDS FOR REDUCING GLUCOSE, CHOLESTEROL AND TRIGLYCERIDE LEVELS IN PLASMA | BEXEL PHARMACEUTICALS, INC. (US) | 2006-08-24 | — | — | WO | disclosed |
| EP-1583529-A2 | AMINO ACID PHENOXY ETHERS | Bexel Pharmaceuticals Inc (US) | 2005-10-12 | — | — | EP | disclosed |
| US-20050096366-A1 | thiazolidin-2,4-diones or -oxazolidin-2,4-diones; obesity, inflammation, autoimmune diseases (multiple sclerosis and rheumatoid arthritis); increase the leptin level; no liver toxicity; inhibits TNF- alpha , IL-1, IL-6, IL-1 beta and cyclooxygenase COX-2; no affinity for PPAR-g; non-adipogenic. | BEXEL PHARMACEUTICALS, INC. | 2005-05-05 | — | — | US | disclosed |
| US-6794401-B2 | thiazolidin-2,4-diones or -oxazolidin-2,4-diones; metabolic Syndrome-X; immunological diseases, inflammation, obesity, hyperlipidemia, hypertension, diabetes; increased leptin level; no liver toxicity; inhibits TNF alpha , IL-6 and IL-1 beta; no affinity for PPAR-g; non-adipogenic | BEXEL PHARMACEUTICALS, INC. | 2004-09-21 | — | — | US | disclosed |
| WO-2004066964-A9 | AMINO ACID PHENOXY ETHERS | BEXEL PHARMACEUTICALS INC (US) | 2004-09-02 | — | — | WO | disclosed |
| WO-2004066964-A2 | AMINO ACID PHENOXY ETHERS | BEXEL PHARMACEUTICALS, INC. (US) | 2004-08-12 | — | — | WO | disclosed |
| US-20040142991-A1 | Amino acid phenoxy ethers | BEXEL PHARMACEUTICALS, INC. | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142991-A1 | Amino acid phenoxy ethers | IL4I1, DNPEP, GPR119 | ITGB3 4367/4885ITGA2B 4201/4885PTPN1 1192/4885 |
| US-20050096366-A1 | thiazolidin-2,4-diones or -oxazolidin-2,4-diones; obesity, inflammation, autoimmune diseases (multiple sclerosis and rheumatoid arthritis); increase the leptin level; no liver toxicity; inhibits TNF- alpha , IL-1, IL-6, IL-1 beta and cyclooxygenase COX-2; no affinity for PPAR-g; non-adipogenic. | PPARA, PPARG, PPARD | ITGB3 3557/4885ITGA2B 3081/4885PTPN1 439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.